Context Therapeutics Inc.
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific antibody (CTIM-76) and small molecule (ONA-XR) investigational medicines. CTIM-76 is an investigational anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAbs) that is intended to redirect T-cell mediated lysis toward malignant cells expressing CLDN6. ONA-XR or onapristone extended release is an investigational medicine for the treatment of ovarian, uterine (endometrial), and breast cancers. These cancers are progesterone-dependent and ONA-XR functions by blocking the progesterone receptor (PR).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
Our Purpose
Our purpose is what weaves us together. It is the single most important reason we come to work each day.
We are united by our passion for helping women with cancer. They deserve better. Their families deserve better. It is our job to help them.
We believe it is possible. We will find a way.